For chronic weight management in adults with obesity, tirzepatide 15 mg delivered a mean 22.5% body weight reduction in the SURMOUNT-1 trial, compared to approximately 15% with semaglutide 2.4 mg in the STEP trials
We also look at body composition, metabolic health, lifestyle habits, and long-term sustainability before recommending changes to a treatment plan. Dr
These two structures share no meaningful sequence overlap, which is why AOD-9604 does not activate GLP-1 receptors and GLP-1 S does not interact with growth hormone pathways the compounds are structurally unrelated despite both being studied in the context of fat metabolism
Also, make sure that you inform your doctor or the lab team about any treatment or medications you are on
If we can identify reliable early clinical cues, nutrition support can begin before lean mass or functional outcomes are affected